An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus.
Latest Information Update: 25 Jul 2023
Price :
$35 *
At a glance
- Drugs Solcitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 May 2019 This trial is completed in Estonia according to European Clinical Trials Database record.
- 01 Nov 2016 Results published in the Lupus
- 04 Mar 2014 Status changed from recruiting to discontinued, as reported by a Galapagos media release.